Thriving in a value-based care environment requires changes to virtually every area of an oncology practice, including the patient experience. Practices in The US Oncology Network provide a variety of non-medical support services to help patients and their families including survivorship, financial counseling, patient assistance programs and advance care planning.
We provide tools that empower practices to succeed in this transformation. Our expertise and comprehensive solutions have been tested and proven in a value-based care environment – ultimately increasing patient satisfaction with their cancer care experience.
Our world-renowned clinical research program is one of the largest community-based oncology research programs in the U.S. We enable practices to offer patients access to the latest cancer clinical trial options in their local communities, providing the opportunity for better outcomes while contributing to the advancement of cancer treatment.
- 72,000 patients enrolled in cancer clinical trials to date
- Contributed to more than 70 FDA-approved cancer therapies, approximately one-third of all FDA-approved oncology therapies
- Hundreds of research programs enrolling patients at any given time
- Accelerated enrollment for cancer clinical trials with highly targeted or rare patient populations
Upcoming Clinical Trials
Breast Cancer - USOR: 19004
A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who receiveClinicalTrials.gov ID
Solid Tumors - USOR: 19079
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHClinicalTrials.gov ID
Breast Cancer - USOR: 18238
A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)ClinicalTrials.gov ID
Biliary Cancer - USOR: 18264
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)ClinicalTrials.gov ID
Lung Cancer - USOR: 17087
BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab StudyClinicalTrials.gov ID
Good things happen when great minds come together, and that’s why we provide a variety of ways for our physicians to connect. Physicians collaborate with their colleagues through physician committees where they determine new ways to lead and guide The US Oncology Network and to shape the future of value-based cancer care. They also interact with one another digitally through The Oncology Portal where approximately 1,400 physicians in The Network share ideas and collaborate on complex cases. Additionally, every year we host network-wide conferences and meetings covering a variety of topics to keep physicians abreast of new developments in cancer patient care.
I have access to a community of physicians and experts going through similar challenges. I am able to reach out to discuss difficult cases; to strategize and expedite solutions.
The US Oncology Network actively advocates regulatory and legislative solutions on behalf of cancer patients, both on the federal and state level, to improve care and to combat proposals that can negatively impact patients. Our highly skilled political experts are dedicated to making sure the voices and concerns of cancer patients are heard in today’s evolving healthcare landscape.
The use of oral chemotherapy drugs in cancer treatment is increasing at a rapid pace. We provide a comprehensive physician dispensing solution so you can provide the convenience of in-office dispensing to your patients. We combine robust pharmacy technology, managed care expertise, expert pharmacy and clinical support, and comprehensive drug and supply fulfillment to help your practice deliver a better, more comprehensive care experience to put you in control of the oral treatment process.
Providing integrated, seamless care under one roof drives better outcomes and increases patient and physician satisfaction, but building a successful multidisciplinary practice is not an easy task. We have a strong history of success in developing integrated oncology practices utilizing a variety of business models. We are committed to enhancing the opportunities for all physicians in The Network to offer integrated value-based cancer care to their patients.
We offer a full range of integrated technology solutions that enable practices to provide patient-focused value-based care. These user-friendly advanced solutions are designed to reduce physician time spent documenting care, freeing up more time for physicians to do what they do best―provide high-quality cancer patient care.